ID   SIR2_MOUSE              Reviewed;         389 AA.
AC   Q8VDQ8; E9PXF5; Q9CXS5; Q9EQ18; Q9ERJ9; U5TP50;
DT   31-OCT-2003, integrated into UniProtKB/Swiss-Prot.
DT   31-OCT-2003, sequence version 2.
DT   18-JUN-2025, entry version 202.
DE   RecName: Full=NAD-dependent protein deacetylase sirtuin-2;
DE            EC=2.3.1.286 {ECO:0000255|PROSITE-ProRule:PRU00236, ECO:0000269|PubMed:17521387, ECO:0000269|PubMed:17574768, ECO:0000269|PubMed:17681146, ECO:0000269|PubMed:21841822, ECO:0000269|PubMed:34059674};
DE   AltName: Full=NAD-dependent protein defatty-acylase sirtuin-2 {ECO:0000305};
DE            EC=2.3.1.- {ECO:0000250|UniProtKB:Q8IXJ6};
DE   AltName: Full=Regulatory protein SIR2 homolog 2;
DE   AltName: Full=SIR2-like protein 2;
DE            Short=mSIR2L2;
GN   Name=Sirt2; Synonyms=Sir2l2;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), AND SUBCELLULAR
RP   LOCATION.
RC   STRAIN=129/Ola;
RX   PubMed=11056054; DOI=10.1006/geno.2000.6360;
RA   Yang Y.H., Chen Y.H., Zhang C.Y., Nimmakayalu M.A., Ward D.C., Weissman S.;
RT   "Cloning and characterization of two mouse genes with homology to the yeast
RT   sir2 gene.";
RL   Genomics 69:355-369(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   STRAIN=C57BL/6J; TISSUE=Embryo;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M., Davis M.J.,
RA   Wilming L.G., Aidinis V., Allen J.E., Ambesi-Impiombato A., Apweiler R.,
RA   Aturaliya R.N., Bailey T.L., Bansal M., Baxter L., Beisel K.W., Bersano T.,
RA   Bono H., Chalk A.M., Chiu K.P., Choudhary V., Christoffels A.,
RA   Clutterbuck D.R., Crowe M.L., Dalla E., Dalrymple B.P., de Bono B.,
RA   Della Gatta G., di Bernardo D., Down T., Engstrom P., Fagiolini M.,
RA   Faulkner G., Fletcher C.F., Fukushima T., Furuno M., Futaki S.,
RA   Gariboldi M., Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N., Hill D.,
RA   Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T., Jakt M.,
RA   Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H., Kitano H.,
RA   Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K., Kurochkin I.V.,
RA   Lareau L.F., Lazarevic D., Lipovich L., Liu J., Liuni S., McWilliam S.,
RA   Madan Babu M., Madera M., Marchionni L., Matsuda H., Matsuzawa S., Miki H.,
RA   Mignone F., Miyake S., Morris K., Mottagui-Tabar S., Mulder N., Nakano N.,
RA   Nakauchi H., Ng P., Nilsson R., Nishiguchi S., Nishikawa S., Nori F.,
RA   Ohara O., Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G.,
RA   Pesole G., Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z.,
RA   Ringwald M., Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B., Sperling S.,
RA   Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K., Tammoja K.,
RA   Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A., Ueda H.R.,
RA   van Nimwegen E., Verardo R., Wei C.L., Yagi K., Yamanishi H.,
RA   Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C., Grimmond S.M.,
RA   Teasdale R.D., Liu E.T., Brusic V., Quackenbush J., Wahlestedt C.,
RA   Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y., Fukuda S.,
RA   Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T., Iida J., Imamura K.,
RA   Itoh M., Kato T., Kawaji H., Kawagashira N., Kawashima T., Kojima M.,
RA   Kondo S., Konno H., Nakano K., Ninomiya N., Nishio T., Okada M., Plessy C.,
RA   Shibata K., Shiraki T., Suzuki S., Tagami M., Waki K., Watahiki A.,
RA   Okamura-Oho Y., Suzuki H., Kawai J., Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), AND ALTERNATIVE SPLICING (ISOFORMS
RP   1 AND 2).
RC   TISSUE=Brain;
RX   PubMed=24177535; DOI=10.1016/j.jmb.2013.10.027;
RA   Rack J.G., Vanlinden M.R., Lutter T., Aasland R., Ziegler M.;
RT   "Constitutive nuclear localization of an alternatively spliced sirtuin-2
RT   isoform.";
RL   J. Mol. Biol. 426:1677-1691(2014).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=C57BL/6J;
RX   PubMed=19468303; DOI=10.1371/journal.pbio.1000112;
RA   Church D.M., Goodstadt L., Hillier L.W., Zody M.C., Goldstein S., She X.,
RA   Bult C.J., Agarwala R., Cherry J.L., DiCuccio M., Hlavina W., Kapustin Y.,
RA   Meric P., Maglott D., Birtle Z., Marques A.C., Graves T., Zhou S.,
RA   Teague B., Potamousis K., Churas C., Place M., Herschleb J., Runnheim R.,
RA   Forrest D., Amos-Landgraf J., Schwartz D.C., Cheng Z., Lindblad-Toh K.,
RA   Eichler E.E., Ponting C.P.;
RT   "Lineage-specific biology revealed by a finished genome assembly of the
RT   mouse.";
RL   PLoS Biol. 7:E1000112-E1000112(2009).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Mammary tumor;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 43-55; 58-69; 79-125; 137-153; 164-174; 213-253;
RP   276-282 AND 348-371, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   STRAIN=C57BL/6J, and OF1; TISSUE=Brain, and Hippocampus;
RA   Lubec G., Klug S., Kang S.U., Sunyer B., Chen W.-Q.;
RL   Submitted (JAN-2009) to UniProtKB.
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic brain;
RX   PubMed=15345747; DOI=10.1074/mcp.m400085-mcp200;
RA   Ballif B.A., Villen J., Beausoleil S.A., Schwartz D., Gygi S.P.;
RT   "Phosphoproteomic analysis of the developing mouse brain.";
RL   Mol. Cell. Proteomics 3:1093-1101(2004).
RN   [8]
RP   FUNCTION IN DEACETYLATION OF FOXO3, CATALYTIC ACTIVITY, FUNCTION IN
RP   REGULATION OF FOXO3 ACTIVITY, INTERACTION WITH FOXO3, SUBCELLULAR LOCATION,
RP   MUTAGENESIS OF HIS-187, AND INDUCTION BY CALORIC RESTRICTION AND OXIDATIVE
RP   STRESS.
RX   PubMed=17521387; DOI=10.1111/j.1474-9726.2007.00304.x;
RA   Wang F., Nguyen M., Qin F.X., Tong Q.;
RT   "SIRT2 deacetylates FOXO3a in response to oxidative stress and caloric
RT   restriction.";
RL   Aging Cell 6:505-514(2007).
RN   [9]
RP   FUNCTION IN DEACETYLATION OF FOXO1, CATALYTIC ACTIVITY, FUNCTION IN
RP   INHIBITION OF ADIPOCYTE DIFFERENTIATION, INTERACTION WITH FOXO1, INDUCTION,
RP   AND TISSUE SPECIFICITY.
RX   PubMed=17681146; DOI=10.1016/j.cmet.2007.07.003;
RA   Jing E., Gesta S., Kahn C.R.;
RT   "SIRT2 regulates adipocyte differentiation through FoxO1
RT   acetylation/deacetylation.";
RL   Cell Metab. 6:105-114(2007).
RN   [10]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=17634366; DOI=10.1523/jneurosci.1254-07.2007;
RA   Werner H.B., Kuhlmann K., Shen S., Uecker M., Schardt A., Dimova K.,
RA   Orfaniotou F., Dhaunchak A., Brinkmann B.G., Mobius W., Guarente L.,
RA   Casaccia-Bonnefil P., Jahn O., Nave K.A.;
RT   "Proteolipid protein is required for transport of sirtuin 2 into CNS
RT   myelin.";
RL   J. Neurosci. 27:7717-7730(2007).
RN   [11]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=16933150; DOI=10.1007/s11064-006-9127-6;
RA   Southwood C.M., Peppi M., Dryden S., Tainsky M.A., Gow A.;
RT   "Microtubule deacetylases, SirT2 and HDAC6, in the nervous system.";
RL   Neurochem. Res. 32:187-195(2007).
RN   [12]
RP   FUNCTION IN DEACETYLATION OF TUBULIN, CATALYTIC ACTIVITY, FUNCTION IN
RP   AXONAL DEGENERATION, AND SUBCELLULAR LOCATION.
RX   PubMed=17574768; DOI=10.1016/j.neuroscience.2007.04.059;
RA   Suzuki K., Koike T.;
RT   "Mammalian Sir2-related protein (SIRT) 2-mediated modulation of resistance
RT   to axonal degeneration in slow Wallerian degeneration mice: a crucial role
RT   of tubulin deacetylation.";
RL   Neuroscience 147:599-612(2007).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=17242355; DOI=10.1073/pnas.0609836104;
RA   Villen J., Beausoleil S.A., Gerber S.A., Gygi S.P.;
RT   "Large-scale phosphorylation analysis of mouse liver.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:1488-1493(2007).
RN   [14]
RP   INTERACTION WITH CDK5, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=18332217; DOI=10.1083/jcb.200707126;
RA   Pandithage R., Lilischkis R., Harting K., Wolf A., Jedamzik B.,
RA   Luscher-Firzlaff J., Vervoorts J., Lasonder E., Kremmer E., Knoll B.,
RA   Luscher B.;
RT   "The regulation of SIRT2 function by cyclin-dependent kinases affects cell
RT   motility.";
RL   J. Cell Biol. 180:915-929(2008).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19144319; DOI=10.1016/j.immuni.2008.11.006;
RA   Trost M., English L., Lemieux S., Courcelles M., Desjardins M.,
RA   Thibault P.;
RT   "The phagosomal proteome in interferon-gamma-activated macrophages.";
RL   Immunity 30:143-154(2009).
RN   [16]
RP   FUNCTION IN DEACETYLATION OF FOXO1, FUNCTION IN INHIBITION OF ADIPOCYTE
RP   DIFFERENTIATION, INTERACTION WITH FOXO1, SUBCELLULAR LOCATION, AND
RP   INDUCTION BY CALORIC RESTRICTION.
RX   PubMed=19037106; DOI=10.1091/mbc.e08-06-0647;
RA   Wang F., Tong Q.;
RT   "SIRT2 suppresses adipocyte differentiation by deacetylating FOXO1 and
RT   enhancing FOXO1's repressive interaction with PPARgamma.";
RL   Mol. Biol. Cell 20:801-808(2009).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-23; SER-25; THR-27; SER-368
RP   AND SER-372, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Brain, Brown adipose tissue, Heart, Kidney, Liver, Lung,
RC   Pancreas, Spleen, and Testis;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and expression.";
RL   Cell 143:1174-1189(2010).
RN   [18]
RP   FUNCTION IN DEACETYLATION OF CDC20 AND FZR1, POSSIBLE FUNCTION AS A TUMOR
RP   SUPPRESSOR, INTERACTION WITH AURKA; CDC20 AND FZR1, DISRUPTION PHENOTYPE,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=22014574; DOI=10.1016/j.ccr.2011.09.004;
RA   Kim H.S., Vassilopoulos A., Wang R.H., Lahusen T., Xiao Z., Xu X., Li C.,
RA   Veenstra T.D., Li B., Yu H., Ji J., Wang X.W., Park S.H., Cha Y.I.,
RA   Gius D., Deng C.X.;
RT   "SIRT2 maintains genome integrity and suppresses tumorigenesis through
RT   regulating APC/C activity.";
RL   Cancer Cell 20:487-499(2011).
RN   [19]
RP   ALTERNATIVE SPLICING (ISOFORMS 1; 2 AND 4), FUNCTION IN DEACETYLATION OF
RP   ALPHA-TUBULIN (ISOFORMS 1; 2 AND 4), ASSOCIATION WITH ALPHA-TUBULIN
RP   (ISOFORMS 2 AND 4), SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND
RP   INDUCTION.
RX   PubMed=21791548; DOI=10.1093/hmg/ddr326;
RA   Maxwell M.M., Tomkinson E.M., Nobles J., Wizeman J.W., Amore A.M.,
RA   Quinti L., Chopra V., Hersch S.M., Kazantsev A.G.;
RT   "The Sirtuin 2 microtubule deacetylase is an abundant neuronal protein that
RT   accumulates in the aging CNS.";
RL   Hum. Mol. Genet. 20:3986-3996(2011).
RN   [20]
RP   FUNCTION IN REGULATION OF PERIPHERAL MYELINATION, CONDITIONAL KNOCKOUT IN
RP   SCHWANN CELL, TISSUE SPECIFICITY, AND INDUCTION.
RX   PubMed=21949390; DOI=10.1073/pnas.1104969108;
RA   Beirowski B., Gustin J., Armour S.M., Yamamoto H., Viader A., North B.J.,
RA   Michan S., Baloh R.H., Golden J.P., Schmidt R.E., Sinclair D.A., Auwerx J.,
RA   Milbrandt J.;
RT   "Sir-two-homolog 2 (Sirt2) modulates peripheral myelination through
RT   polarity protein Par-3/atypical protein kinase C (aPKC) signaling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:E952-961(2011).
RN   [21]
RP   FUNCTION IN DEACETYLATION OF FOXO3, CATALYTIC ACTIVITY, FUNCTION IN
RP   REGULATION OF FOXO3 ACTIVITY, AND MUTAGENESIS OF HIS-187.
RX   PubMed=21841822; DOI=10.1038/onc.2011.347;
RA   Wang F., Chan C.H., Chen K., Guan X., Lin H.K., Tong Q.;
RT   "Deacetylation of FOXO3 by SIRT1 or SIRT2 leads to Skp2-mediated FOXO3
RT   ubiquitination and degradation.";
RL   Oncogene 31:1546-1557(2012).
RN   [22]
RP   REVIEW, AND FUNCTION AS A TUMOR SUPPRESSOR.
RX   PubMed=22943040;
RA   Park S.H., Zhu Y., Ozden O., Kim H.S., Jiang H., Deng C.X., Gius D.,
RA   Vassilopoulos A.;
RT   "SIRT2 is a tumor suppressor that connects aging, acetylome, cell cycle
RT   signaling, and carcinogenesis.";
RL   Transl. Cancer Res. 1:15-21(2012).
RN   [23]
RP   FUNCTION AS A TUMOR SUPPRESSOR, DISRUPTION PHENOTYPE, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=23468428; DOI=10.1101/gad.211342.112;
RA   Serrano L., Martinez-Redondo P., Marazuela-Duque A., Vazquez B.N.,
RA   Dooley S.J., Voigt P., Beck D.B., Kane-Goldsmith N., Tong Q., Rabanal R.M.,
RA   Fondevila D., Munoz P., Kruger M., Tischfield J.A., Vaquero A.;
RT   "The tumor suppressor SirT2 regulates cell cycle progression and genome
RT   stability by modulating the mitotic deposition of H4K20 methylation.";
RL   Genes Dev. 27:639-653(2013).
RN   [24]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=24460154; DOI=10.3109/00016489.2013.861928;
RA   Takumida M., Takumida H., Anniko M.;
RT   "Localization of sirtuins in the mouse inner ear.";
RL   Acta Oto-Laryngol. 134:331-338(2014).
RN   [25]
RP   FUNCTION IN DEACETYLATION OF HISTONE H4 AND ALPHA-TUBULIN, FUNCTION IN
RP   OOCYTE MEIOSIS, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=24334550; DOI=10.1096/fj.13-244111;
RA   Zhang L., Hou X., Ma R., Moley K., Schedl T., Wang Q.;
RT   "Sirt2 functions in spindle organization and chromosome alignment in mouse
RT   oocyte meiosis.";
RL   FASEB J. 28:1435-1445(2014).
RN   [26]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=34059674; DOI=10.1038/s41467-021-23577-z;
RA   Sincennes M.C., Brun C.E., Lin A.Y.T., Rosembert T., Datzkiw D., Saber J.,
RA   Ming H., Kawabe Y.I., Rudnicki M.A.;
RT   "Acetylation of PAX7 controls muscle stem cell self-renewal and
RT   differentiation potential in mice.";
RL   Nat. Commun. 12:3253-3253(2021).
CC   -!- FUNCTION: NAD-dependent protein deacetylase, which deacetylates
CC       internal lysines on histone and alpha-tubulin as well as many other
CC       proteins such as key transcription factors (PubMed:17521387,
CC       PubMed:17574768, PubMed:17681146, PubMed:19037106, PubMed:21791548,
CC       PubMed:21841822, PubMed:22014574, PubMed:24334550, PubMed:34059674).
CC       Participates in the modulation of multiple and diverse biological
CC       processes such as cell cycle control, genomic integrity, microtubule
CC       dynamics, cell differentiation, metabolic networks, and autophagy.
CC       Plays a major role in the control of cell cycle progression and genomic
CC       stability. Functions in the antephase checkpoint preventing precocious
CC       mitotic entry in response to microtubule stress agents, and hence
CC       allowing proper inheritance of chromosomes. Positively regulates the
CC       anaphase promoting complex/cyclosome (APC/C) ubiquitin ligase complex
CC       activity by deacetylating CDC20 and FZR1, then allowing progression
CC       through mitosis. Associates both with chromatin at transcriptional
CC       start sites (TSSs) and enhancers of active genes. Plays a role in cell
CC       cycle and chromatin compaction through epigenetic modulation of the
CC       regulation of histone H4 'Lys-20' methylation (H4K20me1) during early
CC       mitosis. Specifically deacetylates histone H4 at 'Lys-16' (H4K16ac)
CC       between the G2/M transition and metaphase enabling H4K20me1 deposition
CC       by KMT5A leading to ulterior levels of H4K20me2 and H4K20me3 deposition
CC       throughout cell cycle, and mitotic S-phase progression. Deacetylates
CC       KMT5A modulating KMT5A chromatin localization during the mitotic stress
CC       response. Also deacetylates histone H3 at 'Lys-57' (H3K56ac) during the
CC       mitotic G2/M transition. During oocyte meiosis progression, may
CC       deacetylate histone H4 at 'Lys-16' (H4K16ac) and alpha-tubulin,
CC       regulating spindle assembly and chromosome alignment by influencing
CC       microtubule dynamics and kinetochore function. Deacetylates histone H4
CC       at 'Lys-16' (H4K16ac) at the VEGFA promoter and thereby contributes to
CC       regulate expression of VEGFA, a key regulator of angiogenesis.
CC       Deacetylates alpha-tubulin at 'Lys-40' and hence controls neuronal
CC       motility, oligodendroglial cell arbor projection processes and
CC       proliferation of non-neuronal cells (PubMed:17574768, PubMed:21791548).
CC       Phosphorylation at Ser-368 by a G1/S-specific cyclin E-CDK2 complex
CC       inactivates SIRT2-mediated alpha-tubulin deacetylation, negatively
CC       regulating cell adhesion, cell migration and neurite outgrowth during
CC       neuronal differentiation. Deacetylates PARD3 and participates in the
CC       regulation of Schwann cell peripheral myelination formation during
CC       early postnatal development and during postinjury remyelination.
CC       Involved in several cellular metabolic pathways. Plays a role in the
CC       regulation of blood glucose homeostasis by deacetylating and
CC       stabilizing phosphoenolpyruvate carboxykinase PCK1 activity in response
CC       to low nutrient availability. Acts as a key regulator in the pentose
CC       phosphate pathway (PPP) by deacetylating and activating the glucose-6-
CC       phosphate G6PD enzyme, and therefore, stimulates the production of
CC       cytosolic NADPH to counteract oxidative damage. Maintains energy
CC       homeostasis in response to nutrient deprivation as well as energy
CC       expenditure by inhibiting adipogenesis and promoting lipolysis.
CC       Attenuates adipocyte differentiation by deacetylating and promoting
CC       FOXO1 interaction to PPARG and subsequent repression of PPARG-dependent
CC       transcriptional activity (PubMed:17681146, PubMed:19037106). Plays a
CC       role in the regulation of lysosome-mediated degradation of protein
CC       aggregates by autophagy in neuronal cells (PubMed:17681146,
CC       PubMed:19037106). Deacetylates FOXO1 in response to oxidative stress or
CC       serum deprivation, thereby negatively regulating FOXO1-mediated
CC       autophagy (PubMed:17681146, PubMed:19037106). Deacetylates a broad
CC       range of transcription factors and co-regulators regulating target gene
CC       expression (PubMed:34059674). Deacetylates transcriptional factor FOXO3
CC       stimulating the ubiquitin ligase SCF(SKP2)-mediated FOXO3
CC       ubiquitination and degradation (PubMed:17521387, PubMed:21841822).
CC       Deacetylates HIF1A and therefore promotes HIF1A degradation and
CC       inhibition of HIF1A transcriptional activity in tumor cells in response
CC       to hypoxia. Deacetylates RELA in the cytoplasm inhibiting NF-kappaB-
CC       dependent transcription activation upon TNF-alpha stimulation. Inhibits
CC       transcriptional activation by deacetylating p53/TP53 and EP300. Also
CC       deacetylates EIF5A. Functions as a negative regulator on oxidative
CC       stress-tolerance in response to anoxia-reoxygenation conditions. Plays
CC       a role as tumor suppressor (PubMed:22014574, PubMed:23468428). In
CC       addition to protein deacetylase activity, also has activity toward
CC       long-chain fatty acyl groups and mediates protein-lysine
CC       demyristoylation and depalmitoylation of target proteins, such as ARF6
CC       and KRAS, thereby regulating their association with membranes (By
CC       similarity). {ECO:0000250|UniProtKB:Q8IXJ6,
CC       ECO:0000269|PubMed:17521387, ECO:0000269|PubMed:17574768,
CC       ECO:0000269|PubMed:17681146, ECO:0000269|PubMed:19037106,
CC       ECO:0000269|PubMed:21791548, ECO:0000269|PubMed:21841822,
CC       ECO:0000269|PubMed:21949390, ECO:0000269|PubMed:22014574,
CC       ECO:0000269|PubMed:23468428, ECO:0000269|PubMed:24334550,
CC       ECO:0000269|PubMed:34059674}.
CC   -!- FUNCTION: [Isoform 1]: Deacetylates alpha-tubulin.
CC       {ECO:0000269|PubMed:21791548}.
CC   -!- FUNCTION: [Isoform 2]: Deacetylates alpha-tubulin.
CC       {ECO:0000269|PubMed:21791548}.
CC   -!- FUNCTION: [Isoform 4]: Deacetylates alpha-tubulin.
CC       {ECO:0000269|PubMed:21791548}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=N(6)-acetyl-L-lysyl-[protein] + NAD(+) + H2O = 2''-O-acetyl-
CC         ADP-D-ribose + nicotinamide + L-lysyl-[protein];
CC         Xref=Rhea:RHEA:43636, Rhea:RHEA-COMP:9752, Rhea:RHEA-COMP:10731,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:17154, ChEBI:CHEBI:29969,
CC         ChEBI:CHEBI:57540, ChEBI:CHEBI:61930, ChEBI:CHEBI:83767;
CC         EC=2.3.1.286; Evidence={ECO:0000255|PROSITE-ProRule:PRU00236,
CC         ECO:0000269|PubMed:17521387, ECO:0000269|PubMed:17574768,
CC         ECO:0000269|PubMed:17681146, ECO:0000269|PubMed:21841822,
CC         ECO:0000269|PubMed:34059674};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=N(6)-tetradecanoyl-L-lysyl-[protein] + NAD(+) + H2O = 2''-O-
CC         tetradecanoyl-ADP-D-ribose + nicotinamide + L-lysyl-[protein];
CC         Xref=Rhea:RHEA:70567, Rhea:RHEA-COMP:9752, Rhea:RHEA-COMP:15437,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:17154, ChEBI:CHEBI:29969,
CC         ChEBI:CHEBI:57540, ChEBI:CHEBI:141129, ChEBI:CHEBI:189674;
CC         Evidence={ECO:0000250|UniProtKB:Q8IXJ6};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:70568;
CC         Evidence={ECO:0000250|UniProtKB:Q8IXJ6};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=N(6)-hexadecanoyl-L-lysyl-[protein] + NAD(+) + H2O = 2''-O-
CC         hexadecanoyl-ADP-D-ribose + nicotinamide + L-lysyl-[protein];
CC         Xref=Rhea:RHEA:70563, Rhea:RHEA-COMP:9752, Rhea:RHEA-COMP:14175,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:17154, ChEBI:CHEBI:29969,
CC         ChEBI:CHEBI:57540, ChEBI:CHEBI:138936, ChEBI:CHEBI:189673;
CC         Evidence={ECO:0000250|UniProtKB:Q8IXJ6};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:70564;
CC         Evidence={ECO:0000250|UniProtKB:Q8IXJ6};
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000250|UniProtKB:Q8IXJ6};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000250|UniProtKB:Q8IXJ6};
CC   -!- ACTIVITY REGULATION: Inhibited by Sirtinol, A3 and M15 small molecules.
CC       Inhibited by nicotinamide. Inhibited by a macrocyclic peptide inhibitor
CC       S2iL5. Inhibited by EP300-induced acetylation (By similarity).
CC       {ECO:0000250|UniProtKB:Q8IXJ6}.
CC   -!- SUBUNIT: Interacts with CDC20, FOXO3 and FZR1 (PubMed:17521387,
CC       PubMed:22014574). Associates with microtubule in primary cortical
CC       mature neurons (By similarity). Homotrimer. Interacts (via both
CC       phosphorylated, unphosphorylated, active or inactive forms) with HDAC6;
CC       the interaction is necessary for the complex to interact with alpha-
CC       tubulin, suggesting that these proteins belong to a large complex that
CC       deacetylates the cytoskeleton. Interacts with FOXO1; the interaction is
CC       disrupted upon serum-starvation or oxidative stress, leading to
CC       increased level of acetylated FOXO1 and induction of autophagy
CC       (PubMed:17681146, PubMed:19037106). Interacts with RELA; the
CC       interaction occurs in the cytoplasm and is increased in a TNF-alpha-
CC       dependent manner. Interacts with HOXA10; the interaction is direct.
CC       Interacts with YWHAB and YWHAG; the interactions occur in a AKT-
CC       dependent manner and increase SIRT2-dependent TP53 deacetylation.
CC       Interacts with MAPK1/ERK2 and MAPK3/ERK1; the interactions increase
CC       SIRT2 stability and deacetylation activity. Interacts (phosphorylated
CC       form) with KMT5A isoform 2; the interaction is direct, stimulates
CC       KMT5A-mediated methyltransferase activity on histone at 'Lys-20'
CC       (H4K20me1) and is increased in a H(2)O(2)-induced oxidative stress-
CC       dependent manner. Interacts with G6PD; the interaction is enhanced by
CC       H(2)O(2) treatment. Interacts with a G1/S-specific cyclin E-CDK2
CC       complex. Interacts with AURKA, CDK5R1 (p35 form) and CDK5 and HIF1A.
CC       Interacts with the tRNA ligase SARS1; recruited to the VEGFA promoter
CC       via interaction with SARS1 (By similarity). Isoform 2 and isoform 4
CC       associate with microtubules in primary cortical mature neurons.
CC       Interacts with BEX4; negatively regulates alpha-tubulin deacetylation
CC       by SIRT2 (By similarity). {ECO:0000250|UniProtKB:Q8IXJ6,
CC       ECO:0000269|PubMed:17521387, ECO:0000269|PubMed:17681146,
CC       ECO:0000269|PubMed:18332217, ECO:0000269|PubMed:19037106,
CC       ECO:0000269|PubMed:22014574}.
CC   -!- INTERACTION:
CC       Q8VDQ8; Q9JJ66: Cdc20; NbExp=2; IntAct=EBI-911012, EBI-2551389;
CC       Q8VDQ8; Q9R1K5: Fzr1; NbExp=2; IntAct=EBI-911012, EBI-5238560;
CC       Q8VDQ8; O14965: AURKA; Xeno; NbExp=5; IntAct=EBI-911012, EBI-448680;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:19037106,
CC       ECO:0000269|PubMed:24334550, ECO:0000269|PubMed:24460154}. Cytoplasm
CC       {ECO:0000269|PubMed:11056054, ECO:0000269|PubMed:17521387,
CC       ECO:0000269|PubMed:17681146, ECO:0000269|PubMed:19037106,
CC       ECO:0000269|PubMed:24334550, ECO:0000269|PubMed:24460154}. Cytoplasm,
CC       perinuclear region {ECO:0000269|PubMed:16933150}. Perikaryon
CC       {ECO:0000269|PubMed:16933150}. Cytoplasm, cytoskeleton
CC       {ECO:0000250|UniProtKB:Q8IXJ6}. Cell projection
CC       {ECO:0000269|PubMed:16933150}. Cell projection, growth cone
CC       {ECO:0000269|PubMed:18332217}. Myelin membrane
CC       {ECO:0000269|PubMed:16933150}. Cytoplasm, cytoskeleton, microtubule
CC       organizing center, centrosome {ECO:0000250|UniProtKB:Q8IXJ6}.
CC       Cytoplasm, cytoskeleton, spindle {ECO:0000269|PubMed:24334550}.
CC       Chromosome {ECO:0000250|UniProtKB:Q8IXJ6}. Midbody
CC       {ECO:0000269|PubMed:24334550}. Cytoplasm, cytoskeleton, microtubule
CC       organizing center, centrosome, centriole
CC       {ECO:0000250|UniProtKB:Q8IXJ6}. Note=Localizes in the cytoplasm during
CC       most of the cell cycle except in the G2/M transition and during
CC       mitosis, where it is localized in association with chromatin and
CC       induces deacetylation of histone at 'Lys-16' (H4K16ac). Colocalizes
CC       with KMT5A at mitotic foci. Colocalizes with CDK1 at centrosome during
CC       prophase and splindle fibers during metaphase. Colocalizes with Aurora
CC       kinase AURKA at centrosome during early prophase and in the centrioles
CC       and growing mitotic spindle throughout metaphase. Colocalizes with
CC       Aurora kinase AURKB during cytokinesis with the midbody. Colocalizes
CC       with microtubules (By similarity). Deacetylates FOXO3 in the cytoplasm
CC       (PubMed:17521387). Colocalizes with PLP1 in internodal regions of
CC       myelin sheat, at paranodal axoglial junction and Schmidt-Lanterman
CC       incisures (PubMed:16933150). Colocalizes with CDK5R1 in the perikaryon,
CC       neurites and growth cone of hippocampal neurons (PubMed:16933150).
CC       Colocalizes with alpha-tubulin in neuronal growth cone
CC       (PubMed:18332217). Localizes in the cytoplasm and nucleus of germinal
CC       vesicle (GV) stage oocytes (PubMed:24334550). Colocalizes with alpha-
CC       tubulin on the meiotic spindle as the oocytes enter into metaphase, and
CC       also during meiotic anaphase and telophase, especially with the midbody
CC       (PubMed:24334550). {ECO:0000250|UniProtKB:Q8IXJ6,
CC       ECO:0000269|PubMed:16933150, ECO:0000269|PubMed:17521387,
CC       ECO:0000269|PubMed:18332217, ECO:0000269|PubMed:24334550}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=SIRT2.1;
CC         IsoId=Q8VDQ8-1; Sequence=Displayed;
CC       Name=2; Synonyms=SIRT2.2;
CC         IsoId=Q8VDQ8-2; Sequence=VSP_008729;
CC       Name=3;
CC         IsoId=Q8VDQ8-3; Sequence=VSP_055330;
CC       Name=4; Synonyms=SIRT2.3;
CC         IsoId=Q8VDQ8-4; Sequence=VSP_055329;
CC   -!- TISSUE SPECIFICITY: Isoform 1 is weakly expressed in the cortex at
CC       postnatal(P) days P1, P3 and P7, and increases progressively between
CC       P17 and older adult cortex. Isoform 1 is also expressed in heart, liver
CC       and skeletal muscle, weakly expressed in the striatum and spinal cord.
CC       Isoform 2 is not expressed in the cortex at P1, P3 and P7, and
CC       increases strongly and progressively between P17 and older adult
CC       cortex. Isoform 2 is also expressed in the heart, liver, striatum and
CC       spinal cord. Isoform 4 is weakly expressed in older adult cortex and
CC       spinal cords. Expressed in the cortex. Expressed in postnatal sciatic
CC       nerves during myelination and during remyelination after nerve injury.
CC       Expressed in neurons, oligodendrocytes, Schwann cells, Purkinje cells
CC       and in astrocytes of white matter. Strongly expressed in preadipocytes
CC       compared with differentiated adipocytes. Expressed in cerebellar
CC       granule cells. Expressed in the inner ear: in the cochlea, expressed in
CC       types I and V fibrocytes in the spiral ligament (SL) and slightly in
CC       stria vascularis (SV); in the organ of Corti, expressed in some
CC       supporting cells; in the crista ampullaris, expressed in spiral
CC       ganglion cells; also expressed in the endolymphatic sac (ES) epithelial
CC       cells (at protein level). Expressed in the brain, spinal cord, optic
CC       nerve and hippocampus. Strongly expressed in 6-8 week-old ovulated
CC       meiosis II oocytes and weakly expressed in 45-58 week-old ovulated
CC       meiosis II oocytes. Expressed in the cochlea, vestibule and acoustic
CC       nerve of the inner ear. {ECO:0000269|PubMed:16933150,
CC       ECO:0000269|PubMed:17634366, ECO:0000269|PubMed:17681146,
CC       ECO:0000269|PubMed:18332217, ECO:0000269|PubMed:21791548,
CC       ECO:0000269|PubMed:21949390, ECO:0000269|PubMed:24334550,
CC       ECO:0000269|PubMed:24460154}.
CC   -!- DEVELOPMENTAL STAGE: Isoform 1 is expressed in the cortex at 15.5 dpc.
CC       Isoform 2 is not detected in the cortex at 15.5 dpc (at protein level).
CC   -!- INDUCTION: Up-regulated in response to caloric restriction in white and
CC       brown adipose tissues. Up-regulated during cold exposure and down-
CC       regulated in higher ambient temperature in brown adipose tissue. Up-
CC       regulated after beta-adrenergic agonist (isoproterenol) treatment in
CC       white adipose tissue (at protein level). Up-regulated in response to
CC       caloric restriction in adipose tissue and kidney. Up-regulated in
CC       response to oxidative stress. Up-regulated during postnatal sciatic
CC       nerve myelination development and axonal regeneration. Down-regulated
CC       during preadipocyte differentiation. Down-regulated in Schwann
CC       dedifferentiated cells during Wallerian degeneration. Isoform 1 is up-
CC       regulated upon differentiation to a neuron-like phenotype.
CC       {ECO:0000269|PubMed:17521387, ECO:0000269|PubMed:17681146,
CC       ECO:0000269|PubMed:19037106, ECO:0000269|PubMed:21791548,
CC       ECO:0000269|PubMed:21949390}.
CC   -!- PTM: Phosphorylated at phosphoserine and phosphothreonine.
CC       Phosphorylated at Ser-368 by a mitotic kinase CDK1/cyclin B at the G2/M
CC       transition; phosphorylation regulates the delay in cell-cycle
CC       progression. Phosphorylated at Ser-368 by a mitotic kinase G1/S-
CC       specific cyclin E/Cdk2 complex; phosphorylation inactivates SIRT2-
CC       mediated alpha-tubulin deacetylation and thereby negatively regulates
CC       cell adhesion, cell migration and neurite outgrowth during neuronal
CC       differentiation. Phosphorylated by cyclin A/Cdk2 and p35-Cdk5 complexes
CC       and to a lesser extent by the cyclin D3/Cdk4 and cyclin B/Cdk1, in
CC       vitro. Dephosphorylated at Ser-368 by CDC14A and CDC14B around early
CC       anaphase (By similarity). {ECO:0000250|UniProtKB:Q8IXJ6}.
CC   -!- PTM: Acetylated by EP300; acetylation leads both to the decreased of
CC       SIRT2-mediated alpha-tubulin deacetylase activity and SIRT2-mediated
CC       down-regulation of TP53 transcriptional activity.
CC       {ECO:0000250|UniProtKB:Q8IXJ6}.
CC   -!- PTM: Ubiquitinated. {ECO:0000250|UniProtKB:Q8IXJ6}.
CC   -!- DISRUPTION PHENOTYPE: Tissue-specific knockout of SIRT2 in Schwann
CC       cells of early postnatal mice leads to a transient delay in
CC       myelination, a reduction in the nerve conduction velocity and
CC       hyperacetylation of PARD3. The number of dividing Schwann cells in the
CC       developing nerve and alpha-tubulin acetylation are normal
CC       (PubMed:21949390). Mutant mice embryo grow normally and new born are
CC       healthy. Embryonic fibroblasts (MEFs) display reduced cell
CC       proliferation capacity, centrosome amplification and mitotic cell
CC       death. Nude mice inoculated with immortalized MEFs from mutant mice
CC       developed tumors. Adult mutant mice exhibit genomic instability and
CC       chromosomal aberrations, such as double-strand breaks (DSBs), with a
CC       gender-specific spectrum of tumorigenesis; females develop primarily
CC       mammary tumors and males develop tumors in several organs, including
CC       the liver, lung, pancreas, stomach, duodenum and prostate. Drastic
CC       increases of histone H4K16 acetylation and decreases of both histone
CC       methylation (H4K20me1) in metaphasic chromosomes and histone
CC       methylations (H4K20me2/3) in late M/early G1 but also throughout all
CC       phases of the cell cycle (PubMed:23468428).
CC       {ECO:0000269|PubMed:21949390, ECO:0000269|PubMed:22014574,
CC       ECO:0000269|PubMed:23468428}.
CC   -!- SIMILARITY: Belongs to the sirtuin family. Class I subfamily.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF299337; AAG39256.1; -; mRNA.
DR   EMBL; AF302272; AAG32038.1; -; Genomic_DNA.
DR   EMBL; AF302265; AAG32038.1; JOINED; Genomic_DNA.
DR   EMBL; AF302266; AAG32038.1; JOINED; Genomic_DNA.
DR   EMBL; AF302267; AAG32038.1; JOINED; Genomic_DNA.
DR   EMBL; AF302268; AAG32038.1; JOINED; Genomic_DNA.
DR   EMBL; AF302269; AAG32038.1; JOINED; Genomic_DNA.
DR   EMBL; AF302270; AAG32038.1; JOINED; Genomic_DNA.
DR   EMBL; AF302271; AAG32038.1; JOINED; Genomic_DNA.
DR   EMBL; AK014042; BAB29128.1; -; mRNA.
DR   EMBL; KF032392; AGZ02590.1; -; mRNA.
DR   EMBL; AC171210; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC021439; AAH21439.1; -; mRNA.
DR   CCDS; CCDS21055.1; -. [Q8VDQ8-1]
DR   CCDS; CCDS52165.1; -. [Q8VDQ8-4]
DR   CCDS; CCDS85253.1; -. [Q8VDQ8-2]
DR   RefSeq; NP_001116237.1; NM_001122765.2. [Q8VDQ8-2]
DR   RefSeq; NP_001116238.1; NM_001122766.2. [Q8VDQ8-4]
DR   RefSeq; NP_071877.3; NM_022432.4. [Q8VDQ8-1]
DR   RefSeq; XP_036009218.1; XM_036153325.1. [Q8VDQ8-2]
DR   AlphaFoldDB; Q8VDQ8; -.
DR   SMR; Q8VDQ8; -.
DR   BioGRID; 211070; 27.
DR   FunCoup; Q8VDQ8; 1303.
DR   IntAct; Q8VDQ8; 19.
DR   STRING; 10090.ENSMUSP00000072732; -.
DR   ChEMBL; CHEMBL3232691; -.
DR   GlyGen; Q8VDQ8; 2 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site).
DR   iPTMnet; Q8VDQ8; -.
DR   PhosphoSitePlus; Q8VDQ8; -.
DR   SwissPalm; Q8VDQ8; -.
DR   jPOST; Q8VDQ8; -.
DR   PaxDb; 10090-ENSMUSP00000072732; -.
DR   PeptideAtlas; Q8VDQ8; -.
DR   ProteomicsDB; 257014; -. [Q8VDQ8-1]
DR   ProteomicsDB; 257015; -. [Q8VDQ8-2]
DR   ProteomicsDB; 257016; -. [Q8VDQ8-3]
DR   ProteomicsDB; 257017; -. [Q8VDQ8-4]
DR   Pumba; Q8VDQ8; -.
DR   Antibodypedia; 2167; 590 antibodies from 47 providers.
DR   DNASU; 64383; -.
DR   Ensembl; ENSMUST00000072965.5; ENSMUSP00000072732.5; ENSMUSG00000015149.15. [Q8VDQ8-1]
DR   Ensembl; ENSMUST00000122915.8; ENSMUSP00000147217.2; ENSMUSG00000015149.15. [Q8VDQ8-2]
DR   Ensembl; ENSMUST00000170068.9; ENSMUSP00000132783.2; ENSMUSG00000015149.15. [Q8VDQ8-4]
DR   GeneID; 64383; -.
DR   KEGG; mmu:64383; -.
DR   UCSC; uc009fzt.2; mouse. [Q8VDQ8-1]
DR   UCSC; uc012fgx.1; mouse. [Q8VDQ8-4]
DR   AGR; MGI:1927664; -.
DR   CTD; 22933; -.
DR   MGI; MGI:1927664; Sirt2.
DR   VEuPathDB; HostDB:ENSMUSG00000015149; -.
DR   eggNOG; KOG2682; Eukaryota.
DR   GeneTree; ENSGT00940000157514; -.
DR   HOGENOM; CLU_023643_7_4_1; -.
DR   InParanoid; Q8VDQ8; -.
DR   OMA; ATHSCID; -.
DR   OrthoDB; 420264at2759; -.
DR   PhylomeDB; Q8VDQ8; -.
DR   Reactome; R-MMU-2995383; Initiation of Nuclear Envelope (NE) Reformation.
DR   BioGRID-ORCS; 64383; 4 hits in 81 CRISPR screens.
DR   ChiTaRS; Sirt2; mouse.
DR   PRO; PR:Q8VDQ8; -.
DR   Proteomes; UP000000589; Chromosome 7.
DR   RNAct; Q8VDQ8; protein.
DR   Bgee; ENSMUSG00000015149; Expressed in cranial nerve II and 265 other cell types or tissues.
DR   ExpressionAtlas; Q8VDQ8; baseline and differential.
DR   GO; GO:0005814; C:centriole; ISS:UniProtKB.
DR   GO; GO:0005813; C:centrosome; ISS:UniProtKB.
DR   GO; GO:0005694; C:chromosome; ISS:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; ISS:UniProtKB.
DR   GO; GO:0097386; C:glial cell projection; ISS:UniProtKB.
DR   GO; GO:0030426; C:growth cone; IEA:UniProtKB-SubCell.
DR   GO; GO:0000792; C:heterochromatin; ISS:UniProtKB.
DR   GO; GO:0044224; C:juxtaparanode region of axon; ISS:UniProtKB.
DR   GO; GO:0043219; C:lateral loop; ISS:UniProtKB.
DR   GO; GO:0072687; C:meiotic spindle; IDA:UniProtKB.
DR   GO; GO:0005874; C:microtubule; ISS:UniProtKB.
DR   GO; GO:0030496; C:midbody; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IDA:MGI.
DR   GO; GO:0072686; C:mitotic spindle; ISS:UniProtKB.
DR   GO; GO:0043209; C:myelin sheath; IDA:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0033010; C:paranodal junction; IDA:UniProtKB.
DR   GO; GO:0033270; C:paranode region of axon; ISS:UniProtKB.
DR   GO; GO:0043204; C:perikaryon; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-KW.
DR   GO; GO:0043220; C:Schmidt-Lanterman incisure; IDA:UniProtKB.
DR   GO; GO:0005819; C:spindle; ISS:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; ISS:UniProtKB.
DR   GO; GO:0140297; F:DNA-binding transcription factor binding; ISS:UniProtKB.
DR   GO; GO:0035035; F:histone acetyltransferase binding; ISS:UniProtKB.
DR   GO; GO:0004407; F:histone deacetylase activity; IMP:UniProtKB.
DR   GO; GO:0017136; F:histone deacetylase activity, NAD-dependent; ISS:UniProtKB.
DR   GO; GO:0042826; F:histone deacetylase binding; ISS:UniProtKB.
DR   GO; GO:0046970; F:histone H4K16 deacetylase activity, NAD-dependent; ISS:UniProtKB.
DR   GO; GO:0070403; F:NAD+ binding; IEA:Ensembl.
DR   GO; GO:0003950; F:NAD+ poly-ADP-ribosyltransferase activity; IEA:Ensembl.
DR   GO; GO:0140773; F:NAD-dependent protein demyristoylase activity; ISS:UniProtKB.
DR   GO; GO:0140774; F:NAD-dependent protein depalmitoylase activity; ISS:UniProtKB.
DR   GO; GO:0034979; F:NAD-dependent protein lysine deacetylase activity; IDA:UniProtKB.
DR   GO; GO:0033558; F:protein lysine deacetylase activity; IDA:UniProtKB.
DR   GO; GO:0042903; F:tubulin deacetylase activity; IMP:UniProtKB.
DR   GO; GO:0043130; F:ubiquitin binding; ISS:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:Ensembl.
DR   GO; GO:0006914; P:autophagy; IEA:UniProtKB-KW.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0061433; P:cellular response to caloric restriction; IDA:UniProtKB.
DR   GO; GO:0071872; P:cellular response to epinephrine stimulus; IDA:UniProtKB.
DR   GO; GO:0071456; P:cellular response to hypoxia; ISS:UniProtKB.
DR   GO; GO:0034599; P:cellular response to oxidative stress; IDA:UniProtKB.
DR   GO; GO:0006325; P:chromatin organization; IGI:MGI.
DR   GO; GO:0040029; P:epigenetic regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:0016042; P:lipid catabolic process; IMP:UniProtKB.
DR   GO; GO:0051321; P:meiotic cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0022011; P:myelination in peripheral nervous system; IMP:UniProtKB.
DR   GO; GO:0010507; P:negative regulation of autophagy; ISS:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; ISS:UniProtKB.
DR   GO; GO:0045599; P:negative regulation of fat cell differentiation; IMP:UniProtKB.
DR   GO; GO:1900226; P:negative regulation of NLRP3 inflammasome complex assembly; IMP:MGI.
DR   GO; GO:0070446; P:negative regulation of oligodendrocyte progenitor proliferation; ISS:UniProtKB.
DR   GO; GO:0010801; P:negative regulation of peptidyl-threonine phosphorylation; IMP:UniProtKB.
DR   GO; GO:0042177; P:negative regulation of protein catabolic process; ISS:UniProtKB.
DR   GO; GO:2000378; P:negative regulation of reactive oxygen species metabolic process; IMP:UniProtKB.
DR   GO; GO:0045843; P:negative regulation of striated muscle tissue development; ISS:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IMP:UniProtKB.
DR   GO; GO:0044546; P:NLRP3 inflammasome complex assembly; IMP:MGI.
DR   GO; GO:0034983; P:peptidyl-lysine deacetylation; ISS:UniProtKB.
DR   GO; GO:0051987; P:positive regulation of attachment of spindle microtubules to kinetochore; IMP:UniProtKB.
DR   GO; GO:0051781; P:positive regulation of cell division; IMP:UniProtKB.
DR   GO; GO:0043388; P:positive regulation of DNA binding; IDA:UniProtKB.
DR   GO; GO:1900119; P:positive regulation of execution phase of apoptosis; IMP:UniProtKB.
DR   GO; GO:0045723; P:positive regulation of fatty acid biosynthetic process; IEA:Ensembl.
DR   GO; GO:0045836; P:positive regulation of meiotic nuclear division; IMP:UniProtKB.
DR   GO; GO:1900195; P:positive regulation of oocyte maturation; IMP:UniProtKB.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IMP:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:UniProtKB.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; ISS:UniProtKB.
DR   GO; GO:0006476; P:protein deacetylation; IDA:UniProtKB.
DR   GO; GO:0051726; P:regulation of cell cycle; ISS:UniProtKB.
DR   GO; GO:0045598; P:regulation of fat cell differentiation; IMP:MGI.
DR   GO; GO:0031641; P:regulation of myelination; IMP:UniProtKB.
DR   CDD; cd01408; SIRT1; 1.
DR   FunFam; 3.40.50.1220:FF:000005; NAD-dependent deacetylase sirtuin-2; 1.
DR   FunFam; 3.30.1600.10:FF:000013; NAD-dependent protein deacetylase sirtuin-1; 1.
DR   Gene3D; 3.30.1600.10; SIR2/SIRT2 'Small Domain; 1.
DR   Gene3D; 3.40.50.1220; TPP-binding domain; 1.
DR   InterPro; IPR029035; DHS-like_NAD/FAD-binding_dom.
DR   InterPro; IPR050134; NAD-dep_sirtuin_deacylases.
DR   InterPro; IPR003000; Sirtuin.
DR   InterPro; IPR026591; Sirtuin_cat_small_dom_sf.
DR   InterPro; IPR017328; Sirtuin_class_I.
DR   InterPro; IPR026590; Ssirtuin_cat_dom.
DR   PANTHER; PTHR11085:SF6; NAD-DEPENDENT PROTEIN DEACETYLASE SIRTUIN-2; 1.
DR   PANTHER; PTHR11085; NAD-DEPENDENT PROTEIN DEACYLASE SIRTUIN-5, MITOCHONDRIAL-RELATED; 1.
DR   Pfam; PF02146; SIR2; 1.
DR   PIRSF; PIRSF037938; SIR2_euk; 1.
DR   SUPFAM; SSF52467; DHS-like NAD/FAD-binding domain; 1.
DR   PROSITE; PS50305; SIRTUIN; 1.
DR   TreeFam; TF106181; -.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; Autophagy; Cell cycle; Cell division;
KW   Cell membrane; Cell projection; Chromosome; Cytoplasm; Cytoskeleton;
KW   Differentiation; Direct protein sequencing; Meiosis; Membrane;
KW   Metal-binding; Microtubule; Mitosis; NAD; Neurogenesis; Nucleus;
KW   Phosphoprotein; Reference proteome; Transcription;
KW   Transcription regulation; Transferase; Ubl conjugation; Zinc.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000250|UniProtKB:Q8IXJ6"
FT   CHAIN           2..389
FT                   /note="NAD-dependent protein deacetylase sirtuin-2"
FT                   /id="PRO_0000110259"
FT   DOMAIN          57..338
FT                   /note="Deacetylase sirtuin-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00236"
FT   REGION          1..34
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          350..389
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           41..51
FT                   /note="Nuclear export signal"
FT                   /evidence="ECO:0000250"
FT   COMPBIAS        353..369
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        378..389
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        187
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00236"
FT   BINDING         85..89
FT                   /ligand="NAD(+)"
FT                   /ligand_id="ChEBI:CHEBI:57540"
FT                   /evidence="ECO:0000250|UniProtKB:Q8IXJ6"
FT   BINDING         95..97
FT                   /ligand="NAD(+)"
FT                   /ligand_id="ChEBI:CHEBI:57540"
FT                   /evidence="ECO:0000250|UniProtKB:Q8IXJ6"
FT   BINDING         167..170
FT                   /ligand="NAD(+)"
FT                   /ligand_id="ChEBI:CHEBI:57540"
FT                   /evidence="ECO:0000250|UniProtKB:Q8IXJ6"
FT   BINDING         195
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00236"
FT   BINDING         200
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00236"
FT   BINDING         221
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00236"
FT   BINDING         224
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00236"
FT   BINDING         262..263
FT                   /ligand="NAD(+)"
FT                   /ligand_id="ChEBI:CHEBI:57540"
FT                   /evidence="ECO:0000250|UniProtKB:Q8IXJ6"
FT   BINDING         286..288
FT                   /ligand="NAD(+)"
FT                   /ligand_id="ChEBI:CHEBI:57540"
FT                   /evidence="ECO:0000250|UniProtKB:Q8IXJ6"
FT   BINDING         324
FT                   /ligand="NAD(+)"
FT                   /ligand_id="ChEBI:CHEBI:57540"
FT                   /evidence="ECO:0000250|UniProtKB:Q8IXJ6"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8IXJ6"
FT   MOD_RES         23
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         25
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         27
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         53
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q5RJQ4"
FT   MOD_RES         100
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q5RJQ4"
FT   MOD_RES         368
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         372
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   VAR_SEQ         1..37
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:16141072"
FT                   /id="VSP_008729"
FT   VAR_SEQ         6..76
FT                   /note="PSDPLETQAGKVQEAQDSDSDTEGGATGGEAEMDFLRNLFTQTLGLGSQKER
FT                   LLDELTLEGVTRYMQSERC -> R (in isoform 4)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_055329"
FT   VAR_SEQ         236..389
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:24177535"
FT                   /id="VSP_055330"
FT   MUTAGEN         187
FT                   /note="H->A: Abolishes deacetylation of FOXO3. Does not
FT                   inhibit interaction with FOXO3."
FT                   /evidence="ECO:0000269|PubMed:17521387,
FT                   ECO:0000269|PubMed:21841822"
FT   CONFLICT        230
FT                   /note="P -> L (in Ref. 1; AAG32038)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        241
FT                   /note="S -> P (in Ref. 5; AAH21439)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   389 AA;  43256 MW;  15F96635445A1BC0 CRC64;
     MAEPDPSDPL ETQAGKVQEA QDSDSDTEGG ATGGEAEMDF LRNLFTQTLG LGSQKERLLD
     ELTLEGVTRY MQSERCRKVI CLVGAGISTS AGIPDFRSPS TGLYANLEKY HLPYPEAIFE
     ISYFKKHPEP FFALAKELYP GQFKPTICHY FIRLLKEKGL LLRCYTQNID TLERVAGLEP
     QDLVEAHGTF YTSHCVNTSC RKEYTMGWMK EKIFSEATPR CEQCQSVVKP DIVFFGENLP
     SRFFSCMQSD FSKVDLLIIM GTSLQVQPFA SLISKAPLAT PRLLINKEKT GQTDPFLGMM
     MGLGGGMDFD SKKAYRDVAW LGDCDQGCLA LADLLGWKKE LEDLVRREHA NIDAQSGSQA
     PNPSTTISPG KSPPPAKEAA RTKEKEEQQ
//
